ATF4 ‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology · 2025
DOI: 10.1002/1878-0261.70176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Lucia Cottone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University College London Cancer Institute, UK. Hauptthemen laut MEDLINE: Activating Transcription Factor 4, Chordoma, Stress, Physiological. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chordoma Foundation, Sarcoma UK, Bone Cancer Research Trust.
Abstract (Originalsprache)
Chordoma, a rare primary bone malignancy, currently lacks effective targeted therapies. Despite surgical resection and adjuvant radiotherapy, prognosis remains poor. Recent preclinical studies have highlighted potential therapeutic targets, including the transcription factor T‐box transcription factor T (TBXT). However, clinical outcomes associated with therapies targeting TBXT remain underexplored or have been modest, warranting further investigation. In this study, we investigated the therapeutic potential of transfer RNA (tRNA) synthetase inhibitors in chordoma treatment. Focused compound screening identified distinct chemotypes targeting human glutamyl‐prolyl‐tRNA synthetase (EPRS) as being effective in reducing cell viability in chordoma cell lines through a cyclic AMP‐dependent transcription factor (ATF4)‐mediated stress response rather than through TBXT regulation. Mechanistically significant upregulation of ATF4 and associated stress response genes was identified with consecutive pro‐apoptotic DNA damage‐inducible transcript 3 protein (DDIT3)‐mediated cell death. The prototypic EPRS inhibitor halofuginone demonstrated significant tumour growth inhibition in an in vivo patient‐derived xenograft model. These results suggest that targeting metabolic stress pathways via ATF4 activation presents a novel therapeutic approach for chordoma, warranting further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University College London Cancer Institute, UK.
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, National Institute of Health Research Oxford Biomedical Research Unit (BRU), University of Oxford, UK.
- Department of Musculoskeletal Radiology, Royal National Orthopaedic Hospital, Stanmore, UK.
- Oxford Centre for Translational Myeloma Research University of Oxford, UK.
ORCID-Profile: Lucia Cottone, Adam P Cribbs
Förderung
- Chordoma Foundation
- Sarcoma UK
- Bone Cancer Research Trust
- Fondation Leducq
- Chordoma UK
- Medical Research Council
- Cancer Research UK
Zitieren
APA
Cottone, L., Dunford, J., Calcutt, E., Gamble, V., Aksu, F. S., Ligammari, L., Wherry, G., Gaeta, G., Christianson, J. C., Flanagan, A. M., Oppermann, U., & Cribbs, A. P. (2025). ATF4 ‐mediated stress response as a therapeutic vulnerability in chordoma. Molecular Oncology. https://doi.org/10.1002/1878-0261.70176
Vancouver
Cottone L, Dunford J, Calcutt E, Gamble V, Aksu FS, Ligammari L, et al. ATF4 ‐mediated stress response as a therapeutic vulnerability in chordoma. Molecular Oncology. 2025. doi:10.1002/1878-0261.70176
BibTeX
@article{Cottone2025,
author = {Cottone, Lucia and Dunford, James and Calcutt, Eleanor and Gamble, Vicki and Aksu, Filiz Senbabaoglu and Ligammari, Lorena and Wherry, Georgina and Gaeta, Giorgia and Christianson, John C and Flanagan, Adrienne M and Oppermann, Udo and Cribbs, Adam P},
title = {ATF4 ‐mediated stress response as a therapeutic vulnerability in chordoma},
journal = {Molecular Oncology},
year = {2025},
doi = {10.1002/1878-0261.70176}
}
EUVIMED